HBIO - ハ―バ―ド・バイオサイエンス （Harvard Bioscience Inc.） ハ―バ―ド・バイオサイエンスHBIOのチャート
HBIOの企業情報
| symbol | HBIO |
|---|---|
| 会社名 | Harvard Bioscience Inc. （ハ―バ―ド・バイオサイエンス） |
| 分野（sector） | Capital Goods 資本財（工業製品） |
| 産業（industry） | Biotechnology: Laboratory Analytical Instruments |
| 業種 | 先端医療機器_テクノロジ― 医療関連（Health Care） |
| 概要 | 事業概要 ハーバード・バイオサイエンス（Harvard Bioscience Inc.）は世界中の医薬品・バイオ医薬品会社、大学及び政府研究所の生命科学研究を推進するための専門製品、装置及び科学機器の開発・製造・販売に従事するグローバル企業である。同社は850ページのカタログ（及び各種専門カタログ）、ウェブサイト及びGE Healthcare、Thermo Fisher Scientific Inc.とVWR等の流通業者を通じて、100カ国以上の数千人の研究者に製品を販売する。同社の製品は毒性(ADMET)試験及び分子生物学の2つの応用分野をターゲットにする。平成24年2月1日、同社は完全所有子会社Biochrom Ltd.を通してAHN Biotechnologie GmbHの事業を買収した。平成23年7月、同社はCMA Microdialysis AB.の前臨床事業を買収した。 ハ―バ―ド・バイオサイエンスは、米国の医療機器製造会社。製薬会社、バイオテクノ ロジ―会社、大学、政府の実験室など向けに、医薬品研究開発用器具の設計、製造、販売を行う。同社のプロテオミクス関連器具は、たんぱく質および薬剤候補のテストに用いられるADMET (吸収-分布 -代謝-排泄 -毒性) 解析の精製や分析に用いられる。本社は、マサチュ―セッツ州ホリストン。 Harvard Bioscience is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. Its customers range from renowned academic institutions and government laboratories, to the world's leading pharmaceutical, biotechnology and contract research organizations. With operations in North America, Europe, and China, the company sells through a combination of direct and distribution channels to customers around the world. |
| 本社所在地 | 84 October Hill Road Holliston MA 01746 USA |
| 代表者氏名 | James W. Green ジェームズ・W・グリーン |
| 代表者役職名 | Chairman of the Board 取締役会会長 |
| 電話番号 | +1 508-893-8999 |
| 設立年月日 | 1901年 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2000年 |
| 従業員数 | 434人 |
| url | www.harvardbioscience.com |
| nasdaq_url | https://www.nasdaq.com/symbol/hbio |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） 4.39900 |
| 終値（lastsale） | 4.61 |
| 時価総額（marketcap） | 168631946.78 |
| 時価総額 | 時価総額（百万ドル） 156.92650 |
| 売上高 | 売上高（百万ドル） 110.79400 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 212.75150 |
| 当期純利益 | 当期純利益（百万ドル） -4.24500 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Harvard Bioscience Inc. revenues increased 57% to $58.3M. Net loss before extraordinary items increased from $1.4M to $7.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Selling/General/Admin. Expense increase of 73% to $11.7M (expense) Other expense net increase from $105K to $3.1M (expense). |
HBIOのテクニカル分析
HBIOのニュース
Harvard Bioscience, Inc. 2022 Q3 - Results - Earnings Call Presentation (NASDAQ:HBIO) 2022/11/13 01:55:58 Seeking Alpha
The following slide deck was published by Harvard Bioscience, Inc.
Harvard Bioscience, Inc. (HBIO) Q3 2022 Earnings Call Transcript 2022/11/13 01:54:18 Seeking Alpha
Harvard Bioscience, Inc. (NASDAQ:NASDAQ:HBIO) Q3 2022 Earnings Conference Call November 08, 2022, 16:30 ET Company Participants David Sirois - Director, Corporate Accounting & SEC…
Harvard Bioscience Non-GAAP EPS of -$0.01, revenue of $76.9M 2022/11/08 22:23:44 Seeking Alpha
Harvard Bioscience press release (HBIO): Q3 Non-GAAP EPS of -$0.01.Revenue of $76.9M.“Looking to the future, we expect to complete our portfolio optimization and related cost actions…
Harvard Bioscience Announces Third Quarter 2022 Financial Results 2022/11/08 21:01:00 GlobeNewswire
“Fighting through challenging times while building the company and new technologies for the future.” “Fighting through challenging times while building the company and new technologies for the future.”
Earnings Preview: Harvard Bioscience 2022/11/07 17:23:45 Benzinga
Harvard Bioscience (NASDAQ: HBIO ) is set to give its latest quarterly earnings report on Tuesday, 2022-11-08. Here''s what investors need to know before the announcement. Analysts estimate that Harvard Bioscience will report an earnings per share (EPS) of $0.07. Harvard Bioscience bulls will hope to hear the company to announce they''ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for … Full story available on Benzinga.com
Data - Harvard Bioscience Releases Quarterly Earnings Results, Misses Estimates By $0.01 EPS 2022/05/07 19:43:10 Business Mag
Harvard Bioscience announced its quarterly earnings data on Wednesday. The medical instruments supplier reported $0.04 earnings per share for the quarter, missing the consensus…
Harvard Bioscience, Inc. 2022 Q1 - Results - Earnings Call Presentation (NASDAQ:HBIO) 2022/05/05 07:03:17 Seeking Alpha
The following slide deck was published by Harvard Bioscience, Inc.
Harvard Bioscience, Inc. (HBIO) CEO James Green on Q1 2022 Results - Earnings Call Transcript 2022/05/04 16:36:09 Seeking Alpha
Harvard Bioscience, Inc. (NASDAQ:NASDAQ:HBIO) Q1 2022 Earnings Conference Call May 4, 2022 08:00 ET Company Participants David Sirois - Director of Corporate Accounting & SEC Reporting…
Harvard Bioscience Non-GAAP EPS of $0.04 misses by $0.02, revenue of $28.78M beats by $0.05M 2022/05/04 11:08:54 Seeking Alpha
Harvard Bioscience press release (NASDAQ:HBIO): Q1 Non-GAAP EPS of $0.04 misses by $0.02.Revenue of $28.78M (+6.6% Y/Y) beats by $0.05M.
Harvard Bioscience Announces First Quarter 2022 Financial Results 2022/05/04 11:00:00 GlobeNewswire
HOLLISTON, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the first quarter ended March 31, 2022.
Strs Ohio Has $679,000 Stock Holdings in Harvard Bioscience, Inc. (NASDAQ:HBIO) 2021/12/23 09:22:41 Dakota Financial News
Strs Ohio cut its stake in Harvard Bioscience, Inc. (NASDAQ:HBIO) by 7.7% in the 3rd quarter, Holdings Channel.com reports. The fund owned 97,400 shares of the medical instruments suppliers stock after selling 8,100 shares during the quarter. Strs Ohios holdings in Harvard Bioscience were worth $679,000 at the end of the most recent reporting period. []
Harvard Bioscience, Inc. (NASDAQ:HBIO) Shares Bought by Wells Fargo & Company MN 2021/12/12 09:26:42 Transcript Daily
Wells Fargo & Company MN raised its position in Harvard Bioscience, Inc. (NASDAQ:HBIO) by 71.4% during the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 423,186 shares of the medical instruments suppliers stock after acquiring an additional 176,253 shares during the quarter. Wells Fargo & Company MNs holdings in Harvard Bioscience were worth $3,525,000 as []
Analysts Anticipate Harvard Bioscience, Inc. (NASDAQ:HBIO) Will Announce Quarterly Sales of $32.65 Million 2021/12/10 07:40:47 Dakota Financial News
Analysts predict that Harvard Bioscience, Inc. (NASDAQ:HBIO) will report sales of $32.65 million for the current fiscal quarter, Zacks reports. Two analysts have made estimates for Harvard Biosciences earnings, with the lowest sales estimate coming in at $32.50 million and the highest estimate coming in at $32.80 million. Harvard Bioscience reported sales of $30.98 million []
Millennium Management LLC Buys 86,058 Shares of Harvard Bioscience, Inc. (NASDAQ:HBIO) 2021/12/09 09:26:47 Transcript Daily
Millennium Management LLC lifted its stake in shares of Harvard Bioscience, Inc. (NASDAQ:HBIO) by 144.6% during the second quarter, Holdings Channel.com reports. The firm owned 145,562 shares of the medical instruments suppliers stock after acquiring an additional 86,058 shares during the period. Millennium Management LLCs holdings in Harvard Bioscience were worth $1,213,000 as of its []
13,509 Shares in Harvard Bioscience, Inc. (NASDAQ:HBIO) Acquired by Prudential Financial Inc. 2021/12/02 10:52:45 Dakota Financial News
Prudential Financial Inc. purchased a new stake in Harvard Bioscience, Inc. (NASDAQ:HBIO) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 13,509 shares of the medical instruments suppliers stock, valued at approximately $113,000. Several other hedge funds and other institutional []